BioDelivery Sciences International Competitors, Revenue, Alternatives and Pricing

Claim your profile


Total Funding:$105.5M
Lead Investor(s):William Blair & Company, L.L.C.

State Ranking

Estimated Revenue & Financials

  • BioDelivery Sciences International's estimated annual revenue is currently $5.6M per year.
  • BioDelivery Sciences International received $50.0M in venture funding in May 2018.
  • BioDelivery Sciences International's estimated revenue per employee is $30,054
  • BioDelivery Sciences International's total funding is $105.5M.

Employee Data

  • BioDelivery Sciences International has 185 Employees.
  • BioDelivery Sciences International grew their employee count by 7% last year.
  • BioDelivery Sciences International currently has 4 job openings.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingOnline ReviewPricing
Advertise Here
BioDelivery Sci...
Quality Chemica...
LMK Clinical Re...
PMG Research
3D Communicatio...
WEP Clinical
Tanner Pharma G...
Nuventra Pharma...
Flow Sciences
Missing a competitor? Contribute!?

BioDelivery Sciences ("BDSI"®) is a specialty pharmaceutical company with a focus in the areas of pain management and addiction medicine. We are utilizing our novel and proprietary BioErodible MucoAdhesive (BEMA®) and other drug delivery technologies to develop and commercialize, either on our own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs.



Number of Employees


Revenue (est)


Current Jobs


Employee Growth %


Total Funding







BioDelivery Sciences International News

09/03/2019 - How Much Are BioDelivery Sciences International, Inc. (NASDAQ:BDSI) Insiders Taking Off The Table?

So we'll take a look at whether insiders have been buying or selling shares in BioDelivery Sciences International, Inc. (NASDAQ:BDSI).

09/08/2019 - BioDelivery Sciences Reports Strong Second Quarter 2019 ...

08, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial-stage specialty ...

09/03/2019 - BioDelivery Sciences International, Inc. (BDSI) CEO Herm Cukier on Q2 2019 Results - Earnings Call Transcript

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) Q2 2019 Earnings Conference Call August 8, 2019 4:30 PM ET. Company ...

BioDelivery Sciences International Funding

DateAmountRoundLead InvestorsReference
2002-07-09$9.4MPublic OfferingArticle
2005-07-19$7.0MUndisclosedClinical Development Capital LArticle
2006-02-17$7.0MUndisclosedCDC IV LLCArticle
2012-11-29$40.0MUndisclosedWilliam Blair & Company L L CArticle
2015-06-02$20.7MUndisclosedMidCap FinancialArticle
2017-02-24$75.0MUndisclosedCRG LP,Article
2018-05-18$50.0MUndisclosedWilliam Blair & Company, L.L.C.Article

BioDelivery Sciences International Executive Hires

2005-08-24Mark A. SirgoChief Executive OfficerArticle
2007-04-11Al MedwarVP MarketingArticle
2010-09-08Benny WardEVP Business/Strategic DevelopmentArticle
2013-07-24Adrian HepnerVP Clinical Research/Regulatory AffairArticle
2013-10-22Ernest R. De PaolantonioCFO/Corporate SecretaryArticle
2013-12-04David AchesonVP Sales / Managed MarketsArticle
2014-10-13J. Chris PrueEVP Regulatory Affairs /Quality AssuranceArticle
2015-04-29Sarah DeRossettVP Clinical Research/Medical AffairsArticle
2015-06-09Stephana E. PattonVP/Geneal CounselArticle
2015-07-15Enoch BorteyVP Clinical Biostatistics/Data SystemsArticle
2015-12-04Joseph M. LockhartVP Manufacturing and Supply ChainArticle
2015-12-17Niraj VasishtSVP/CTOArticle
2016-12-15Peter GinsbergVice President of Business DevelopmentArticle
2017-12-21Scott PleshaPresident/Sales & Marketing functionsArticle
2018-05-08Herm CukierCEOArticle
2018-07-31Thomas SmithChief Medical OfficerArticle
2019-01-16Terry CoelhoChief Financial OfficerArticle